

Clinical practice guidelines development: the first Tunisian experience

Dr Asma BEN BRAHEM

EBHC Taormina

07/11/2019



INEAS

الهيئة الوطنية للتقييم و الاعتماد في المجال الصحي
Instance Nationale de l'Evaluation
& de l'Accréditation en Santé

Background

INEAS

- Public authority
- Scientifically independent
- Ministry of health



Aims

Management of chronic heart failure

Reduce mortality

Reduce morbidity

Quality of life improvement



STCCCV

Société Tunisienne de Cardiologie
& de Chirurgie Cardio-Vasculaire



المعتمدة من قبل
الهيئة الوطنية للتقييم والإعتماد في المجال الصحي

FORMULAIRE DE DEMANDE RECOMMANDATIONS PROFESSIONNELLES

Date de la demande:	
Identité du demandeur:	
Qualité / Fonction:	
Etablissement:	
- Téléphone:	
- Bureau:	
- Personnel:	
E-mail:	

Note:

L'achèvement de ce formulaire est conçu comme une approche multidisciplinaire et collaborative. Certains types de soumissions peuvent ne pas exiger que toutes les sections soient complétées. Il est conseillé de consulter les unités et/ou services concernés afin de mener à bien la finalisation de ce formulaire.

1/ Sujet proposé (*)

.....

2/ Type de la demande (*)

- Guide de pratique clinique / Clinical Practice Guideline (CPG)
 Parcours de soins / Care pathways (integrated pathways)

3/ Motif de la demande (*)

.....

4/ Population cible (*)

.....

5/ Données épidémiologiques (si disponible)

- Incidence:
- Prévalence:
-

Methodology

Guideline Adaptation: A Resource Toolkit



| Prepared by the ADAPTE Collaboration 2009
| (www.adapte.org)
| Version 2.0

Table 1. THE AGREE INSTRUMENT

Scope and purpose

1. The overall objective(s) of the guideline is (are) specifically described.
2. The clinical question(s) covered by the guideline is (are) specifically described.
3. The patients to whom the guideline is meant to apply are specifically described.

Stakeholder involvement

4. The guideline development group includes individuals from all relevant professional groups.
5. The patients' views and preferences have been sought.
6. The target users of the guideline are clearly defined.
7. The guideline has been piloted among target users.

Rigour of development

8. Systematic methods were used to search for evidence.
9. The criteria for selecting the evidence are clearly described.
10. The methods for formulating the recommendations are clearly described.
11. The health benefits, side effects, and risks have been considered in formulating the recommendations.
12. There is an explicit link between the recommendations and supporting evidence.
13. The guideline has been externally reviewed by experts prior to its publication.
14. A procedure for updating the guideline is provided.

Clarity and presentation

15. The recommendations are specific and unambiguous.
16. The different options for management of the condition are clearly described.
17. Key recommendations are easily identifiable.
18. The guideline is supported with tools for application.

Applicability


19. The potential organizational barriers in applying the recommendations have been discussed.
20. The potential cost implications of applying the recommendations have been considered.
21. The guidelines present key review criteria for monitoring and/or audit purposes.

Editorial independence

22. The guideline is editorially independent from the funding body.
23. Conflicts of interest of guideline development members have been recorded.






AGREE II



Results


Identification
Screening
Eligibility
Included






Publication & diffusion

- www.ineas.tn
- www.g-i-n.net



Limits

- **INEAS ressources:**
 - Human ressources
 - Financial ressources
- **Resistance to change**
 - Some medical associations
 - Some policy makers
- **Capacity buildings of healthcare professionals**



Clinical /Care Pathways



Clinical Pathways



Clinical pathways are standardised, evidence-based multidisciplinary management plans, which identify an appropriate sequence of clinical interventions, timeframes, milestones and expected outcomes for an homogenous patient group (Queensland Health Clinical Pathways Board definition 2002).





Thank you